BioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY24 Earnings Guidance
BioMarin Pharmaceutical (NASDAQ:BMRN) has updated its FY24 earnings guidance, projecting EPS between $0.10 and $0.25, contrasting with the consensus estimate of $0.23. Revenue guidance is set at $750 million to $825 million against a consensus of $800 million. The company recently reported a quarterly EPS of $0.77, surpassing expectations. Stocks have seen a slight dip recently, continuing to reflect a moderate buy rating from analysts, with a consensus price target of $81.26.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $3.10-$3.25 for the period, compared to the consensus earnings per share estimate of $3.23. The company issued revenue guidance of $2.750-$2.825 billion, compared to the consensus revenue estimate of $2.80 billion.
BioMarin Pharmaceutical Price Performance
- Are Gene Therapy Stocks The Market's Next Big Winners?
Shares of BioMarin Pharmaceutical stock traded down $1.22 during trading on Wednesday, hitting $90.38. 1,217,338 shares of the stock traded hands, compared to its average volume of 1,827,818. The stock has a market cap of $17.16 billion, a price-to-earnings ratio of 85.60 and a beta of 0.32. BioMarin Pharmaceutical has a 52 week low of $73.68 and a 52 week high of $99.56. The company has a quick ratio of 1.95, a current ratio of 3.05 and a debt-to-equity ratio of 0.11. The firm's fifty day moving average is $86.37 and its 200-day moving average is $85.06.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million during the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. Research analysts expect that BioMarin Pharmaceutical will post 2.35 EPS for the current fiscal year.
Wall Street Analyst Weigh In
- Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
A number of equities research analysts have recently commented on the stock. Scotiabank upped their price objective on shares of BioMarin Pharmaceutical from $85.00 to $86.00 and gave the company a sector perform rating in a report on Tuesday, August 6th. Robert W. Baird downgraded BioMarin Pharmaceutical from an outperform rating to a neutral rating and dropped their price target for the stock from $104.00 to $72.00 in a research report on Friday, May 17th. Stifel Nicolaus upped their price objective on shares of BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company a buy rating in a research note on Wednesday, August 21st. Baird R W lowered BioMarin Pharmaceutical from a strong-buy rating to a hold rating in a research note on Friday, May 17th. Finally, Evercore ISI upped their price target on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an outperform rating in a research note on Tuesday, August 6th. Eight research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $105.26.
Read Our Latest Stock Report on BioMarin Pharmaceutical
About BioMarin Pharmaceutical
(Get Free Report)- Top Biotech Stocks: Exploring Innovation Opportunities
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles
- Five stocks we like better than BioMarin Pharmaceutical
- Do ETFs Pay Dividends? What You Need to Know
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- How Can Investors Benefit From After-Hours Trading
- Introduction to Fibonacci Retracement Levels
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ My grim warning about AI stocks (From Porter & Company) (Ad)
Should you invest $1,000 in BioMarin Pharmaceutical right now?
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
